Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605730/
https://www.ncbi.nlm.nih.gov/pubmed/36310663
http://dx.doi.org/10.2147/DDDT.S394059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605730/
https://www.ncbi.nlm.nih.gov/pubmed/36310663
http://dx.doi.org/10.2147/DDDT.S394059

Ejemplares similares